A5010663592- Inflammatory Bowel Disease
- Microscopic Colitis
- Eosinophilic Esophagitis
- Adolescent and Pediatric Healthcare
- Autoimmune and Inflammatory Disorders Research
- Colorectal Cancer Screening and Detection
- Immunodeficiency and Autoimmune Disorders
- Digestive system and related health
- Antibiotic Use and Resistance
- Diagnosis and treatment of tuberculosis
- Celiac Disease Research and Management
- Respiratory viral infections research
- Diverticular Disease and Complications
- Biosimilars and Bioanalytical Methods
- Sepsis Diagnosis and Treatment
- Gastric Cancer Management and Outcomes
- Dupuytren's Contracture and Treatments
- Congenital gastrointestinal and neural anomalies
- Acute Lymphoblastic Leukemia research
- Liver Disease Diagnosis and Treatment
- Pharmaceutical studies and practices
- Genetic factors in colorectal cancer
Stanford University
2024-2025
Stanford Medicine
2025
UCSF Benioff Children's Hospital
2019-2024
University of California, San Francisco
2019-2024
Whittington Health NHS Trust
2019
Background/Objectives: In adolescent patients with ulcerative colitis refractory to anti-tumor necrosis factor (TNF) therapy, episodes of acute severe (ASUC) require hospitalization or surgery. Upadacitinib can be a potential colectomy-sparing agent in adult ASUC receiving intensified dosing. Methods: This case series evaluates clinical outcomes rescue upadacitinib dosing ASUC. We included adolescents admitted anti-TNF treated 30 mg twice daily upadacitinib. The primary outcome was the...
Vedolizumab (VDZ) and ustekinumab (UST) are second-line treatments in pediatric patients with ulcerative colitis (UC) refractory to antitumor necrosis factor (anti-TNF) therapy. Pediatric studies comparing the effectiveness of these medications lacking. Using a registry from ImproveCareNow (ICN), global research network inflammatory bowel disease, we compared UST VDZ anti-TNF UC.
Ustekinumab (UST), a human monoclonal antibody against interleukin-12 and 23, is approved to treat adult patients with psoriasis or Crohn disease (CD). Outcomes data for off-label use in pediatric CD are limited.We conducted retrospective cohort study analyze the long-term efficacy of UST, including dose adjustments, treatment medically refractory CD. Adverse events were documented.We identified 40 treated UST between January 1, 2016 December 31, 2019. Electronic medical records reviewed...
Few studies report the impact of depression on inflammatory bowel disease (IBD)-related hospitalizations. We evaluated association between and pediatric IBD-related Our primary aim was to test hypothesis that is associated with hospital length stay (LOS); our secondary goal evaluate if patients are at higher risk for undergoing additional imaging procedures.Data were extracted from 2012 Kids Inpatient Database (KID), largest nationally representative publicly available all-payer inpatient...
Patient-reported outcomes (PROs) are vital in assessing disease activity and treatment inflammatory bowel (IBD). However, manual extraction of these PROs from the free-text clinical notes is burdensome. We aimed to improve data curation information electronic health record, making it more available for research quality improvement. This study compare traditional natural language processing (tNLP) large models (LLMs) extracting three IBD (abdominal pain, diarrhea, fecal blood) across two institutions.
Abstract INTRODUCTION Societal guidelines recommend against the use of 5-aminosalicylate (5-ASA) therapy for pediatric patients with Crohn’s Disease (pCD). Previous trials showed no benefit 5-ASAs inducing remission and similar one-year relapse rates when compared placebo. Conversely, biologics are recommended as first-line due to higher rates, corticosteroid-sparing effects, potential alter disease progression. AIMS We aimed describe in pCD associated patterns biologic corticosteroid a...
Biosimilar tumor necrosis factor inhibitors (b-TNFi) reduce healthcare costs and maintain equal efficacy when compared to their originator counterparts (o-TNFi). Current practice is start patients on a slower standard infusion rate during the initial transition from an o-TNFi b-TNFi. There knowledge gap around switching rapid biosimilar in pediatric inflammatory bowel disease (IBD) population.
<h3>Introduction</h3> Biological agents have revolutionised the treatment of inflammatory bowel disease (IBD) with usage continually rising. Decisions regarding de-escalation therapy require balancing financial implications, risks long-term immunosuppression against risk relapse, and potential unsuccessful re-challenge. Approximately one third IBD patients relapse within 12 months discontinuing biologics.<sup>1</sup> We aimed to identify factors associated remission. <h3>Methods</h3> The...
<h3>Background</h3> The rising prevalence of type 2 diabetes (T2DM) and its complications including non-alcoholic fatty liver disease (NAFLD) is now a leading cause cirrhosis hepatocellular cancer. Prompt identification fibrosis in patients with NAFLD essential for directing specialist care improving outcomes. Although T2DM major risk factor NAFLD, there are no guidelines on screening this population. We aimed to identify the abnormalities attending secondary clinic. In addition we used...
There is limited data on the effect of depression inflammatory bowel disease (IBD)-related hospitalizations. This cross-sectional study aims to evaluate pediatric IBD-related hospitalization, with primary focus length hospital stay (LOS). Secondary goals were if patients are at higher risk for undergoing additional imaging and procedures. [SV1] Data was extracted from 2012 Kids Inpatient Database (KID), largest nationally representative inpatient database in United States. Hospitalizations...
In paediatric patients with acute gastroenteritis (AGE), ondansetron use decreases the need for intravenous fluids, reduces hospitalisations and shortens illness duration. Oral rehydration is also known to have excellent outcomes mild moderate dehydration secondary AGE. Although these interventions are recommended in guidelines from international professional societies, baseline data at our clinic showed that <2% of were offered ondansetron, few received appropriately detailed...